highly variable drugs-Cmax [Regulatives / Guidelines]

posted by nuka2020 – United Arab Emirates, 2020-11-19 11:09 (677 d 11:10 ago) – Posting: # 22067
Views: 1,621

According to the GCC guidelines a wider range of Cmax(i.e 75-133%) can be acceptable for HVDP, where it has been demonstrated that the within- subject variability for Cmax of the reference compound in the study is >30%.
But, i have a study which was performed as per Eu guidelines and accordingly, the acceptance criteria for Cmax can be widened to a maximum of 69.84 – 143.19%. Accordingly, the results of Cmax is: 70.46%-141.90%
Need suggestion whether this studies can be acceptable as per GCC guidelines?? :confused::confused:

Complete thread:

UA Flag
Activity
 Admin contact
22,391 posts in 4,685 threads, 1,595 registered users;
online 14 (0 registered, 14 guests [including 2 identified bots]).
Forum time: Tuesday 23:20 CEST (Europe/Vienna)

Statistics. A sort of elementary form of mathematics which consists of
adding things together and occasionally squaring them.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5